WuXi Biologics (Cayman) Inc. (Stock Code: 2269) released a positive profit alert indicating that, based on a preliminary assessment of its unaudited consolidated management accounts for the year ended December 31, 2025, total revenue is expected to rise by approximately 16.7% to RMB21,790 million. The gross profit margin rate is projected to expand by about 5 percentage points to 46.0%, with adjusted gross profit anticipated to increase by around 25.5% to RMB10,638 million year-on-year.

According to the same assessment, the company’s profit is expected to climb by approximately 45.3% to RMB5,733 million, while profit attributable to equity shareholders is anticipated to rise by around 46.3% to RMB4,908 million. After adjustments for share-based compensation, foreign exchange gains and losses, and certain one-time costs, the non-IFRS adjusted net profit is forecast to increase by around 22.0% to RMB6,586 million.

WuXi Biologics (Cayman) Inc. attributes these improvements to multiple factors, including effective execution of its “Follow and Win the Molecule” strategies, wider service offerings that include research and discovery, fast-growing technology platforms, the utilization of newly expanded manufacturing capacities (including facilities in Europe), cost-efficiency measures, and investment gains. Final results for the 2025 fiscal year are scheduled to be published on March 24, 2026, and the previously mentioned figures remain subject to final adjustments. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.